Pear Therapeutics said this month that it closed a $64 million Series C round led by Temasek.
The Boston-based company plans to use its newly-acquired funds to support the global commercialization of its reSET prescription digital therapeutics and fund its clinical pipeline, as well as buy up additional assets.
Get the full story at our sister site, Drug Delivery Business News.
The post Pear Therapeutics closes $64m Series C round appeared first on MassDevice.